Summary
The leading meeting for basic and translational heart failure science in Europe.
Welcome
"The HFA Winter Meeting has been a long-standing tradition and has emerged as the best basic and translational heart failure meeting in Europe. The tradition started in 1983, initiated by Professor Dirk Brutsaert (founding president of the Heart Failure Association of the ESC, 2004–2008), the first official meeting was chaired by Sir James Whyte Black, who developed the first b-blockers and was awarded the Nobel Prize for Physiology or Medicine in 1988. The format is usually composed of formal lectures from the invited faculty, and poster presentations from selected abstracts, with interactions at lunch, dinners and free time.
As participation is reserved for active presenters only, this is a very interactive meeting with a lot of room for fruitful discussions, scientific boot camps, and opportunities for new stimulating collaborations. The presence of scientists with different scientific backgrounds makes this meeting a huge opportunity for brainstorming and thinking outside the box, with novel visions and concepts and therapeutic targets for HF discussed and the possibilities of translation into the clinical arena. Participants will hear the most novel scientific advancements on the topic of heart failure".
Prof. Carlo Gabriele Tocchetti
HFA Board Member and Course Director, HFA Winter Meeting
Timeline
- Preliminary programme available: August 2023
- Call for abstracts: early August to 4 October 2023
- Abstract results announcement: mid-November 2023
- HFA Winter Research Meeting: 24–26 January 2024
Venue
The meeting will take place at:
Eurotel Victoria Les Diablerets
Le Vernex 3, 1865 Les Diablerets, Suisse
Telephone : +41 24 492 37 21
Abstracts
Abstracts will be accepted from early August to 4 October 2023.
Registration
Attendance at the HFA Winter Meeting is restricted to invited faculty and abstract presenters. Accepted abstracts will be announced in November 2023.
The attendance fee for all abstract presenters is €800 (including VAT).
Our mission: To reduce the burden of cardiovascular disease.